Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gilead Sciences, Inc. (NASDAQ: GILD) shares dropped on Tuesday as the company announced it had signed a voluntary licensing agreement with five generic drugmakers to manufacture and supply its drug Remdesivir in 127 countries.

Gilead Shares Drop As It Agrees To 'Royalty-Free' Coronavirus Drug Licence With Generic Drugmakers In 127 Countries

Mylan

Mylan will distribute the drug as a COVID-19 treatment in 127 low- and middle-income countries.

Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally

The deal is "royalty-free" until WHO says the Covid-19 outbreak is no longer a global health crisis or "until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19."

Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries

Shares of Gilead Sciences Inc. GILD, -1.47% were down 1.2% in trading on Tuesday after the drugmaker listed on its website five generic drugmakers that will produce remdesivir, its experimental COVID-19 treatment.

Gilead announces non-U.S. deals with five generic drugmakers for remdesivir

With the markets in turmoil over the coronavirus, no stock has embodied the unpredictability of today more than Gilead Sciences (NASDAQ: GILD).

Here's A Bullish Options Play On Gilead

Allstate

Costco

Dollar General

Home Depot

Kroger

Altria

NextEra Energy

RCI Hospitality

Under any other circumstance, sell in May and go away may be considered a sound strategy. In this crisis, though, you may want to keep these stocks to buy for the long haul.

9 Enduring Stocks That You Shouldn’t Sell in May

Biotech company Gilead Sciences gained Food and Drug Administration emergency use authorization for its coronavirus treatment, remdesivir, in early May. Is Gilead stock a buy?

Gilead Is Creating A Coronavirus Drug Stockpile — Is Gilead Stock A Buy?

AbbVie

Amgen

Biotech stocks are often high-risk, high-reward investments that have binary outcomes based on one or a handful of drug or device candidates in development.

Biotech Stock Rally Is Crushing Short Sellers

There are reasons to be concerned about the initial distribution model for Gilead Sciences' recently green-lit Remdesivir treatment for COVID-19.

The Government Will Distribute Gilead's Remdesivir. This Could Be Bad News for Investors

Alphabet

Novavax

In this time of pandemic, investors can do well by seeking out companies that are doing good.

A COVID-19 Strategy: Invest in Companies That Are Doing Good

The Department of Health and Human Services on Saturday said the states with the greatest number of COVID-19 cases have been allotted doses of Gilead Sciences Inc.

HHS: States to dispense Gilead's remdesivir to hospitals

Gilead: Strategic Update - Focus On 'Defend/Extend' HIV Franchise

Vertex Pharmaceuticals

These hot biotech stocks should be near the top of your list.

3 Top Biotech Stocks to Buy in May

Hint: it's something that happens once every quarter.

What Investors Are Missing About Gilead Sciences

The attacks on Gilead reflect a growing trend of state-backed hackers targeting intelligence related to a treatment for coronavirus.

Gilead Sciences Targeted By Iranian-Linked Hackers: Report

Eli Lilly

The National Institute of Allergy and Infectious Diseases (NIAID) said Friday it is testing Gilead Sciences Inc.

Government to test remdesivir with Lilly drug in COVID-19 patients

Hackers linked to Iran have targeted staff at U.S. drugmaker Gilead Sciences Inc in recent weeks, according to publicly-available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy a treatment for the COVID-19 virus.

Exclusive: Iran-linked hackers recently targeted coronavirus drugmaker Gilead - sources

Gilead Sciences Inc. (NASDAQ: GILD) took another big step forward in its treatment for COVID-19 on Friday when a Japanese regulatory body approved that treatment.

Gilead Sciences Gains Remdesivir Approval in Japan

Last Friday, Gilead received U.S. FDA authorization for emergency use of its wide-spectrum anti-viral drug Remdesivir for severe cases of COVID-19 after the drug showed some effectiveness in reducing recovery times.

COVID Treatments: Gilead Stock Doesn’t Reflect Optimism About Remdesivir

Abbott Labs

Lockheed Martin

Emerson Radio

Netflix

Coronavirus Roundtable - Opportunities Around The World

In a matter of weeks, remdesivir has gone from a shelved, failed hepatitis C treatment to the center of a national effort to treat patients suffering from covid-19, the illness caused by the novel coronavirus.

The company may have a breakout drug, but how do you market a pandemic treatment?

It remains unknown whether the drug is safe or effective in treating coronavirus.

Japan Approves Remdesivir For Use On Severe COVID-19 Patients

Even After FDA Approval Market Keeps Underestimating Gilead's Antiviral

Moderna

The Food and Drug Administration cleared Moderna to begin a Phase 2 study of its coronavirus vaccine on Thursday, sending MRNA stock flying.
The post Covid Report: Moderna Soars On Vaccine Test; Gilead Nabs Japan Approval appeared first on Investor's Business Daily.

Covid Report: Moderna Soars On Vaccine Test; Gilead Nabs Japan Approval

AstraZeneca

Bristol-Myers

Clovis Oncology

Merck

Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.

News for Gilead Sciences Stock (GILD)